Overview

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Status:
Completed
Trial end date:
2020-01-15
Target enrollment:
Participant gender:
Summary
An open-label study of volanesorsen (ISIS 304801) administered subcutaneously to participants with FCS.
Phase:
Phase 3
Details
Lead Sponsor:
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.
Collaborators:
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.